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Abstract: Group 1 allergens of house dust mites (HDM) are globally significant triggers of allergic disease.
They are considered as initiator allergens because their protease activity enables the development of
allergy to a spectrum of unrelated allergens from various sources. This initiator-perpetuator function
identifies Group 1 HDM allergens as attractive drug design targets for the first small-molecule
approach directed towards a non-human, root cause trigger of allergic disease. The purpose of
this study was to: (i) identify exemplar inhibitors of these allergens using Der p 1 as a design
template, and (ii) characterise the pharmacological profiles of these compounds using in vitro and
in vivo models relevant to allergy. Potent inhibitors representing four different chemotypes and
differentiated by mechanism of action were investigated. These compounds prevented the ab initio
development of allergy to the full spectrum of HDM allergens and in established allergy they inhibited
the recruitment of inflammatory cells and blunted acute allergic bronchoconstriction following aerosol
challenge with the full HDM allergen repertoire. Collectively, the data obtained in these experiments
demonstrate that the selective pharmacological targeting of Der p 1 achieves an attractive range of
benefits against exposure to all HDM allergens, consistent with the initiator-perpetuator function of
this allergen.
Keywords: Der p 1; airway inflammation; eosinophil; house dust mite; allergens; allergen delivery
inhibitor
1. Introduction
A compelling case demonstrates that as well as binding allergen-specific IgE, some allergens
possess bioactivities which are essential to the development and maintenance of sensitisation to a wide
range of unrelated allergens [1,2]. These bioactivities define the function of the allergenic protein in
its host source, but upon interaction with structural elements of human mucosal surfaces they can
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cause disease, especially in individuals possessing an underlying genetic predisposition. Consequently,
the broader ranging these bioactivities are, the greater their influence on the pathogenesis of allergic
disease. Such allergens typically exert serodominance, generating high titre allergen-specific IgE,
but by being permissive for the effects of unrelated allergens they also serve as wide-ranging
initiator-perpetuators of allergy [1]. This ‘functionalist’ concept of a cadre of allergens that act as
bioinitiators of sensitisation to other, comparatively effete, allergens is well established in experimental
models that have given insights into the mechanisms of immunological and non-immunological
collateral priming, adjuvancy, or bystander effects [3–6]. The functionalist view of allergens is also
understood from the perspective of longitudinal epidemiological surveys of polysensitisation where
a temporal progression in reactivity to different allergens is recognised, and where discrete initiator
allergens are linked strongly to the development of disease [7–10].
Group 1 allergens from HDM have been most extensively investigated as initiator allergens [2,11,12].
In HDM, they function as digestive enzymes and are excreted in faecal pellets which are inhalable by
humans. Impaction of inhaled HDM faecal pellets on the airway surface releases the protease allergen,
which is resistant to inactivation by natural antiprotease defences of the airways, achieving a high
localised concentration of the enzyme. The cysteine protease activity of these allergens increases the
probability of detection by dendritic antigen presenting cells creates a signalling environment in the
airways which favours the programming and then maintenance of immune responses with an allergic
phenotype [1,11,13].
The detection of inhaled allergens by antigen presenting cells is facilitated by Group 1 HDM
allergens because they cleave interepithelial tight junctions (TJs) by directly attacking the extracellular
domains of the TJ adhesion proteins [14]. The ensuing non-selective increase in epithelial permeability
enhances the probability of contact between any inhaled allergen and antigen presenting cell networks
whose dendrites become increasingly exposed to the milieu of the airway lumen [12]. A further
consequence is that dendritic and other cells accumulate in increasing numbers in the airway [13].
Additionally, the effects on TJs enable allergens to engage receptors of the innate immune system
which ordinarily exhibit basolateral distribution. Ligation of these receptors activates signalling which
upregulates the expression of inflammatory cytokines and facilitates the release of other mediators.
Some pro-allergic cytokines, notably IL-13, downregulate the expression of TJ adhesion proteins
thus exacerbating the cycle of allergen delivery to antigen presenting cells and innate signalling
receptors [15]. Similar permeability events have been reported for the nasal epithelium and skin [16,17]
and linkage to allergy is suggested by claudin-1 expression being inversely proportional to the
Th2 polarisation of immune responses [18,19]. The recent discovery that Group 1 HDM allergens
have prothrombinase activity provides new insight into how this polarisation to allergic responses
occurs and suggests a novel mechanism which might contribute to epithelial–mesenchymal cell
transition and airway remodelling driven primarily by the innate effects of certain allergens [2,12,20,21].
The combination of allergen delivery, polarisation of adaptive responses and immunodominance by
Group 1 HDM allergens is consistent with them being initiators of allergic responses to themselves
and to unrelated allergens through a process of collateral priming of immune responses [2,11,12,14].
The identification and characterisation of initiator allergens creates opportunities for the design of
small molecule interventions designed to target the agents whose activities promote and sustain
allergic disease [2,11,12,22]. A prominent appeal of such an approach is that the targeting of
a non-human, root cause trigger of disease should combine an attractive safety profile with a
significantly wider range of efficacy benefits than can be achieved by targeting discrete downstream
effector pathways (e.g., leukotriene antagonists, cytokine-specific biologics), or by the less selective
action of corticosteroids [12,22]. Attempting this type of intervention is now feasible following
biological advances in understanding the molecular basis of allergenicity, and chemical advances in
structure-based protease inhibitor design [2,11,12,22]. Thus, for the first time since the invention of
allergen immunotherapy by Noon and Freeman in 1911, is it possible to envisage small-molecule
pharmacotherapy aimed directly at the causative, non-human, aspect of allergy [23].
Int. J. Mol. Sci. 2018, 19, 3166 3 of 34
We have recently disclosed the design and synthesis of novel inhibitors of Group 1 HDM allergens
which target the allergy initiator-sustainer mechanisms by inhibiting their proteolytic activity [2,12,22].
Conveniently, the high degree of identity or similarity in the amino acid sequences of the Group 1
allergens from dust mites of different species means that they comprise a single target for the purposes
of inhibitor design [2,11,12]. As inhalant allergens with dominant roles as initiator-sustainers of
allergic asthma and perennial allergic rhinitis, direct administration of the inhibitors to the airways
should neutralise inhaled allergen molecules before significant interactions with the airway lining can
occur. For these reasons, our inhibitor design programme sought to identify potent molecules which
possessed the pharmaceutical credentials for delivery by inhalation, together with other attributes
(e.g., selectivity, safety, and endurance) necessary for clinical developability. These compounds have
been named ‘allergen delivery inhibitors’ (ADIs), reflecting an important facet of the bioactivity of
Group 1 HDM allergens [2,11,12,22].
In the present paper, we compare the effects of exemplar inhibitors arising from this drug design
programme. Additionally, we describe the properties of a range of novel reagents and analytical
methods that will facilitate further investigations of the Group 1 HDM allergens using approaches
which offer substantial improvements over tool compounds available hitherto.
2. Results
2.1. Degradation of ADZ 50,059 by Group 1 HDM Allergens and Its Inhibition
Initially, we investigated the cleavage of ADZ 50,059 by Der p 1 and Der f 1 to establish whether the
substrate exhibited similar behaviour against Group 1 allergens from two globally-significant species
of HDM. We were also interested in comparing the susceptibility of the substrate to a range of other
enzymes of interest. Functional similarity of the allergens was confirmed by their comparable, low
micromolar, KM values (Table 1), consistent with predictions from their aligned amino acid sequences.
ADZ 50,059 was a poor substrate for the serine proteases trypsin and chymotrypsin but, as anticipated
from bioinformatics and computational chemistry, a more effective substrate for off-target human
cysteine peptidases related to Der p 1 and Der f 1. That cathepsin B was less favoured than cathepsins
K and S was also anticipated because of the combined effects of its slightly lower degree of sequence
identity with the HDM allergens (~25% for mature sequence) compared to cathepsins K or S (31–34%)
and differences in the size of substrate binding pockets in these enzymes.
Figure 1A,B shows that the rate of degradation of ADZ 50,059 by Der p 1 was retarded in the
presence of ADZ 50,000 or Compound 3. The ability of ADZ 50,000 to inhibit Der p 1, Der f 1 and
other proteases was quantified by comparison of pseudo first order rate constants ( kobs
[I] ). As expected,
ADZ 50,000 was highly reactive with Der p 1 and Der f 1, but essentially inactive against selected
serine peptidases (Table 2). Against cathepsins B and S it showed limited (<10-fold) intrinsic selectivity
over Der p 1, whereas against cathepsins H, K, and L the difference in reactivity was considerable
(~100–10,000-fold). For comparison, the generic cysteine peptidase inhibitor E-64, which has been used
by others as a Der p 1 inhibitor tool, is significantly less reactive with Der p 1 than ADZ 50,000 ( kobs
[I]
(3.4 ± 0.23) × 105 M−1 s−1) and has little selectivity.
A snapshot of ADZ 50,000 compared to a range of ‘standard’ protease inhibitors is shown in
Figure 1C which depicts their effects on the cleavage of substrate ADZ 50,059 by a natural mixture of
HDM allergens (i.e., containing both cysteine and serine peptidase activity). Most of the proteolytic
activity was inhibited by ADZ 50,000, whereas E-64 was only a moderate inhibitor. While we did not
elect to ensure that either compound completely titrated the catalytic sites of Der p 1 in the mixture,
their relative performance in this assay is consistent with pseudo first order kinetic rate constant
measurements reported above. Antipain and chymostatin, which discriminate poorly between serine
and cysteine proteases, were effective inhibitors of substrate cleavage, whereas TLCK and TPCK,
which show marginally better preference but not clear selectivity for serine proteases, were less
effective and were augmented by ADZ 50,000 but not E-64.
Int. J. Mol. Sci. 2018, 19, 3166 4 of 34
Int. J. Mol. Sci. 2018, 19, x 5 of 36 
 
 
Figure 1. Proteolysis of ADZ 50,059 by Der p 1 or mixed HDM allergens and its inhibition. (A) 
Progress curves for cleavage by Der p 1 in the absence or presence of a range of concentrations of 
ADZ 50,000. (B) Inhibition of Der p 1 by Compound 4. In both (A) and (B), the grey lines show data 
in the absence of added enzyme. Progress curves are depicted as a single data set which was replicated 
twice on a single 96-well plate and >3 times for each compound on separate occasions. (C) Proteolysis 
of ADZ 50,059 by mixed HDM allergens containing 40 nM Der p 1 and the effects of inhibitors tested 
at the following concentrations: ADZ 50,000 (50 µM); E-64 (200 µM); antipain (200 µM); TLCK (1 mM); 
chymostatin (50 µM); TPCK (50 µM). Data are mean ± s.e. (n = 4). (D) Example progress curves for the 
cleavage of N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide by chymotrypsin (green triangles) and its 
modification by 400 µM AEBSF (purple squares) or 40 µM ADZ 50,000 (blue squares). Corresponding 
Figure 1. Proteolysis of ADZ 50,059 by Der p 1 or mixed HDM allergens and its inhibition. (A) Progress
curves for cleavage by Der p 1 in the absence or presence of a range of concentrations of ADZ 50,000.
(B) Inhibition of Der p 1 by Compound 4. In both (A) and (B), the grey lines show data in the absence of
added enzym . Progress curves re depicted as a single data set which was replicated twice on a single
96-well plate and >3 times for each compound on separate occasions. (C) Proteolysis of ADZ 50,059 by
mixed HDM allergens containing 40 nM Der p 1 and the effects of inhibitors tested at the following
concentrations: ADZ 50,000 (50 µM); E-64 (200 µM); antipain (200 µM); TLCK (1 mM); chymostatin
(50 µM); TPCK (50 µM). Data are mean ± s.e. (n = ). (D) Example progress curv f r the cleavage
of N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide by chymotrypsin (green triangles) and its modification
by 400 µM AEBSF (purple squares) or 40 µM ADZ 50,000 (blue squares). Corresponding data are
presented for native Der p 1 (black circles) with AEBSF (orange circles) or ADZ 50,000 (magenta
triangles) showing that this substrate is insensitive to pure Der p 1. (E) Example initial rates of
reaction as determined from an experiment similar to that depicted in (D) confirming the resistance
to degradation of the chymotrypsin substrate and the lack of inhibitory activity of ADZ 50,000 on
chymotrypsin. (F) Processing of N-Bz-Phe-Val-Arg-p-nitroanilide by trypsin (blue), native Der p 1
(green), and recombinant Der p 1 (yellow) and the effects of 80 µM AEBSF or 8 µM ADZ 50,000.
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Although not optimised for selectivity, it is clear that ADZ 50,000 lacks the indiscriminate
behaviour of common inhibitor tools and highlights the limitations of those compounds in the study
of HDM protease allergens. As shown in Figure 1D,E it does not inhibit the initial degradation of
N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide by chymotrypsin, whereas AEBSF is, as expected, a potent
inhibitor. In contrast, Der p 1 is inactive against this substrate (Figure 1D,E). Figure 1F illustrates the
degradation of N-Bz-Phe-Val-Arg-p-nitroanilide by trypsin which is strongly inhibited by AEBSF but
not by ADZ 50,000. This substrate is also degraded by both native Der p 1 and recombinant Der p 1 in
reactions which are insensitive to AEBSF but fully attenuated by ADZ 50,000. These experiments show
that despite a lack of formal optimisation and having a mechanism which involves an electrophilic
attack on the catalytic residue, ADZ 50,000 discriminates well between its intended Der p 1 target and
serine peptidases. Furthermore, there is no serine protease activity associated with Der p 1.
Table 1. Measured KM values for ADZ 50,059 against Der p 1 and a panel of cysteine and
serine peptidases.
Enzyme KM (µM)
Der p 1 15.4 ± 2.1
Der f 1 29.0 ± 2.6
Cathepsin B 40.9 ± 4.5
Cathepsin L 8.0 ± 1.3
Cathepsin S 12.3 ± 1.8
Trypsin 46.6 ± 2.9
Chymotrypsin 132.1 ± 22.7
Data are mean ± s.e. mean from 4 determinations.
Table 2. Measured activity of ADZ 50,000 against Der p 1, Der f 1, and a panel of off-target cysteine
and serine peptidases.
Enzyme Kobs/[I] (M−1 s−1)
Der p 1 2 × 108
Der f 1 1.9 × 108
Cathepsin B 3.7 × 107
Cathepsin S 2.1 × 107
Cathepsin L 1.7 × 106
Cathepsin H 1.5 × 106
Cathepsin K 1.6 × 104
Thrombin inactive at ≤50 µM
Trypsin inactive at ≤50 µM
Chymotrypsin inactive at ≤50 µM
2.2. Effects of Der p 1 and Der p 2 on Barrier Properties of Human Airway Epithelial Cells and Its Modulation
by ADZ 50,000
At confluence, Calu-3 cells developed an appreciable TER (>1000 Ohms.cm2) consistent with
the well-established properties of these cells [24]. Application of Der p 1 to the apical side of the
monolayers significantly reduced TER, whereas Der p 2 in greater molar equivalence neither had any
effect itself nor altered the response to Der p 1 (Figure 2A). Pre-treatment of Der p 1 with ADZ 50,000
fully prevented the reduction in TER in monolayers treated with either Der p 1 alone or a combination
of Der p 1 and Der p 2 (Figure 2A).
Addition of Der p 1 to confluent monolayers of Calu-3 cells with a well-developed TER was
associated with transepithelial passage of the allergen such that it was detectable in the basolateral
medium in the Transwell™ (Figure 2B). Consistent with the inability of Der p 2 to influence the
TER changes evoked by Der p 1, the extent of Der p 1 transepithelial permeation was unaffected by
Der p 2 (Figure 2B). However, addition of ADZ 50,000 significantly reduced the amount of Der p 1
recoverable in the basolateral medium (Figure 2B). In cells treated with Der p 2 alone, a small amount of
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immunoreactive material was detected in the basolateral compartment but this finding was similar to
data from untreated control cells, suggesting that it may be due to cross-reactive material released from
the cells (Figure 2C). Der p 2 only became detectable in the basolateral compartment in appreciable
amounts when mixtures of Der p 1 and Der p 2 were added to the apical side of the chamber, and this
response was significantly reduced by ADZ 50,000 (Figure 2C). These effects mirror the action of
Der p 1 on TER and its own transepithelial disposition. The tendency to a larger flux of Der p 2 reflects
the fact that it was present in excess over Der p 1 and that as a smaller molecule, and in the absence of
other factors, its permeability would be expected to be greater than that of Der p 1.Int. J. Mol. Sci. 2018, 19, x 7 of 36 
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Immunoreactive Der p 1 (i-Der p 1) detected in the basolateral chamber of Transwells after 2 h 
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* p < 0.001 vs. vehicle control; † p < 0.01 vs. Der p 1 and Der p 2 in the absence of ADZ 50,000. (C) as 
(B), but measuring i-Der p 2, * p < 0.01 vs. vehicle control; † p < 0.01 vs. Der p 1/Der p 2 mixture. (D) 
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its inhibition by AEBSF (100 µM). Data are mean ± s.e. mean on 4 replicate tests on a single batch of 
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showing that AEBSF has an inhibitory effect on the serine peptidase contaminant associated with Der 
p 2. * p < 0.001 vs. vehicle control; † p < 0.001 vs. Der p 1 and Der p 2 in the absence of AEBSF. In (A–
C) and in (E), data are shown as values from individual experiments with the mean ± s.e. indicated 
by the cross-hair and whiskers. 
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Our next aim was to study the susceptibility of the first extracellular domain of claudin 1 to 
cleavage by Der p 1. This domain was chosen because claudin 1 is expressed in the airways and is a 
useful representative of claudins with a ‘sealing type’ function [12]. Incubation of CLD1.1 with Der p 
1 resulted in the generation of multiple peptide fragments which are summarised in Table 3. These 
sites are well conserved in the claudin repertoire of human lung. Unexpectedly, inspection of the 
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Figure 2. Effect of ADZ 50, on TER and t t lial disposition of Der p 1 and Der p 2 in
the Calu-3 human airway epithelial cel li . trasting actions of Der p 1 (2 µM) and Der p 2
(2.8 µM) on TER and the i i i i of Der p 1-mediated ffects by ADZ 5 ,000 (1 µM). * p < 0.001,
† p < .01 vs. vehicle control. Vehicle comprised serum-free EMEM co taining 5 mM cysteine.
(B) Immunoreactive Der p 1 (i-Der p 1) detected in the basolateral chamber of Transwells after 2 h
incubation with apically-applied Der p 1, Der p 2 or Der p 1 ith Der p 2 and the effect of ADZ 50,000.
* p < 0.001 vs. vehicle control; † p < 0.01 vs. Der p 1 and Der p 2 in the absence of ADZ 50,000. (C) as
(B), but measuring i-Der p 2, * p < 0.01 vs. vehicle control; † p < 0.01 vs. Der p 1/Der p 2 mixture.
(D) Detection of contaminant serine peptidase activity in a commercial preparation of native Der p 2
and its inhibition by AEBSF (100 µM). Data are mean ± s.e. mean on 4 replicate tests on a single
batch of allergen using N-Bz-Phe-Val-Arg-p-nitroanilide as substrate. * p < 0.05. (E) measurement of
basolateral i-Der p 1 after the application of a mixture of Der p 1 and Der p 2 to the apical surface of
calu-3 cells showing that AEBSF has an inhibitory effect on the serine peptidase contaminant associated
with Der p 2. * p < 0.001 vs. vehicle control; † p < 0.001 vs. Der p 1 and Der p 2 in the absence of
AEBSF. In (A–C) and in (E), data are shown as values from individual experiments with the mean ±
s.e. indicated by the cross-hair and whiskers.
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In passing, we observed that some batches of commercially-sourced Der p 2 were associated
with protease activity which could be inhibited by treatment with AEBSF (Figure 2D). As Der p 2
is not proteolytic per se, this most likely reflects the presence of contaminants with the potential to
confound investigations of the bioactivity of Der p 2. An example of this is shown in Figure 2E where
the transepithelial flux of Der p 1 evoked by a mixture of Der p 1 and Der p 2 was partially inhibited
by AEBSF, which is not an inhibitor of Der p 1 (Figure 1F).
2.3. Cleavage of CLD1.1 by Der p 1
Our next aim was to study the susceptibility of the first extracellular domain of claudin 1 to
cleavage by Der p 1. This domain was chosen because claudin 1 is expressed in the airways and is
a useful representative of claudins with a ‘sealing type’ function [12]. Incubation of CLD1.1 with
Der p 1 resulted in the generation of multiple peptide fragments which are summarised in Table 3.
These sites are well conserved in the claudin repertoire of human lung. Unexpectedly, inspection
of the fragments generated revealed similarities to a facile cleavage site identified by us in occludin
(viz. Leu-Leu) [14,25] suggesting that it could be cleavage hot spot in both families of TJ adhesion
protein. Formation of all claudin cleavage products was prevented by inactivation of Der p 1 with
ADZ 50,000, but not by its treatment with AEBSF.
Table 3. Cleavage sites for Der p 1 identified in CLD1.1. Peptides identified by LC-MS-MS were used to
identify positional cleavages indicated by single letter amino acid notation in the first column. Implied
subsite specificity of Der p 1 is indicated for positions S4–S4′ . Similarity with potential cleavage sites
in the first extracellular domain of occludin are highlighted in yellow. Grey and blue shading denote
non-prime and prime subsite interactions of Der p 1 relative to the cleavage site (Schecter and Berger
nomenclature).
TJ Loop and Identified Cleavage S4 S3 S2 S1 S1′ S2′ S3′ S4′
CLD1.1
SLLN.LSST Ser Leu Leu Asn Leu Ser Ser Thr
FDSL.LNLS Phe Asp Ser Leu Leu Asn Leu Ser
LSST.LQAT Leu Ser Ser Thr Leu Gln Ala Thr
IVTA.QAMY Ile Val Thr Ala Gln Ala Met Tyr
IQCK.VFDS Ile Gln Cys Lys Val Phe Asp Ser
RIYS.YAGD Arg Ile Tyr Ser Tyr Ala Gly Asp
CVSQ.STGQ Cys Val Ser Gln Ser Thr Gly Gln
VTAQ.AMYE Val Thr Ala Gln Ala Met Tyr Glu
Occludin 1.1
GTSL.LGGS Gly Thr Ser Leu Leu Gly Gly Ser
2.4. Cytokine Release from Airway Epithelial Cells and Its Modulation By ADZ 50,000
We next investigated the ability of Der p 1 to evoke the release of IL-6 and IL-8 from airway
epithelial cells and the effect of ADZ 50,000 (Figure 3A–C). The choice of the A549 cell line for these
experiments was informed by literature precedent which had established them as a basis for the
investigation of cytokine release by Der p 1 [26]. However, the release of both cytokines showed
large variation between experiments, with some cells being refractory to activation whereas others
were not. The reasons for this separation into responders and non-responders are unknown but are
not related to the proteolytic competence of the Der p 1 preparations. Under identical conditions,
Der p 2 was inactive in all tests and was similarly lacking in efficacy when other treatment protocols
were evaluated in both A549 and calu-3 cells. Thrombin and trypsin, representative activators of
PAR-1/PAR-4 and PAR-2, respectively, elicited no detectable change in IL-8 release. However, IL-6 was
detectable after addition of thrombin (Figure 3A), implying the existence of PAR-1/PAR-4-dependent
signal transduction in its release. Similar results to those described above were obtained when cells
were incubated with these enzymes for up to 24 h and when studies were performed in calu-3 cells.
Despite the variation in cytokine release overall, those experiments which were characterised by
Int. J. Mol. Sci. 2018, 19, 3166 8 of 34
responder cells enabled us to examine whether these effects were dependent on Der p 1. Figure 3C
shows the inhibitory effect of ADZ 50,000 on the release of IL-6 and IL-8 for cell passages identified as
cytokine responders, consistent with the protease activity of Der p 1 in enabling their release.Int. J. Mol. Sci. 2018, 19, x 9 of 36 
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ADZ 50,000 treatment on cytokine release (IL-8, black; IL-6, red) elicited by Der p 1 in designated 
responder experiments. Data from individual experiments are shown. * p < 0.05, † p < 0.01 vs. 
corresponding inhibitor-free control. In all cases, cross-hairs and whiskers denote mean ± s.e. mean, 
respectively. 
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2.5. Lung Function and Cell Recruitment Studies in Sensitized Rats
In brown Norway rats, sensitisation to mixed HDM allergens produced variable effects on
post-study total serum IgE compared to the vehicle-treated group (Figure 4A) but there were
consistent elevations in serum allergen-specific IgE and IgG2a compared to the vehicle-treated group
(Figure 4B,C).
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Figure 4. Effects of allergen delivery inhibitors on airway responses to either an extract of mixed HDM
allergens or Der p 1 in brown Norway rats. (A–C) Po t- e sitisation s rum concentrations of IgE,
allergen-specific IgE and allergen-specific IgG2a in animals assigned to the treatment groups for the lung
function investigations performed in (D–F). Assignment to drug treatment was made blind with respect
to these data which were obtained after the conclusion of the lung function stu ies. * p < 0.001–0.05
vs. control animals assigned to sham sensitisation with vehicle (shown in grey). (D) Changes in
airway resistance following challenge of HDM-sensitised animals with an i.t. aerosol of mixed HDM
allergens (10 µg Der p 1 equivalent) or vehicle. Animals were treated with ADZ 50,000 (×10 molar
ratio to Der p 1), Compound 1 (×250 molar ratio to Der p 1), Compound 2 (×200 molar ratio to
Der p 1), Compound 3 (×8 molar ratio to Der p 1) prior to HDM challenge. * p < 0.05 vs. control
animals assigned to sham sensitisation and challenge with vehicle (data shown in grey). † p < 0.01–0.05
vs. challenged with mixed HDM allergens. (E,F) Changes in airway resistance to acetylcholine and
adenosine, respectively, measured 1 h after allergen challenge in the six treatment groups. (G–J) BAL
cell profiles and BAL fluid recovery in animals sensitised to mixed HDM allergens and challenged
with Der p 1 (10 µg in 100 µL) with or without prior treatment with ADZ 50,000 (×2.5 molar ratio to
Der p 1) or Compound 1 (×8 molar ratio to Der p 1). * p < 0.01–0.05 vs. control animals assigned to
sham sensitisation and challenge with vehicle or vehicle challenge in animals sensitised to mixed HDM
(data shown in grey). † p < 0.05 vs. animals challenged with Der p 1. Data are shown as results for
individual animals with mean ± s.e. indicated by cross-hair and whiskers.
Int. J. Mol. Sci. 2018, 19, 3166 10 of 34
Challenge of sensitised rats with an intratracheal aerosol of mixed HDM allergens (HDM 10)
evoked an acute increase in lung resistance (Figure 4D) which returned to baseline within 60 min.
This effect of HDM challenge was significantly greater than the response to vehicle seen in sensitised
animals. In contrast, lung resistance changes in animals challenged with HDM allergens treated with
ADZ 50,000 or Compounds 1, 2, and 3, were significantly reduced compared to the control challenge
with HDM 10 (Figure 4D). As a further component of the study, we investigated whether challenge
was associated with a change in airways reactivity to ACh or Ado. Although both stimuli suggested a
tendency to increased airways reactivity 1 h after HDM challenge, these effects were not significant
when compared to sensitised animals challenged with vehicle due to the high level of variability in
responses. A similar pattern was evident in animals challenged simultaneously with HDM allergens
and ADI compounds (Figure 4E,F). There was no change in airways reactivity to ACh or Ado in
animals tested 24 h after HDM allergen challenge.
In the next study, we investigated the effect of two ADI compounds on the Der p 1-dependent
recruitment of cells to the airways of rats sensitised to the full extract of HDM allergens. Our previous
investigations had shown that the optimum time for monitoring the eosinophil component of this
response, in which we were most interested, was 48 h following aerosol delivery of the allergen
challenge. Electively, we therefore performed BAL at this time after challenge. The total number of
nucleated cells in recovered BAL fluid was increased in animals challenged with Der p 1 compared
to vehicle-challenged, HDM-sensitised rats, or naïve animals receiving only the BAL procedure.
This response was partially attenuated in animals challenged with Der p 1 that had been treated with
either ADZ 50,000 or Compound 3 (Figure 4G). A similar outcome was seen when eosinophil numbers
were considered, with their recruitment significantly inhibited by the ADIs (Figure 4H). In contrast,
the neutrophil recruitment response was not attenuated by ADIs (Figure 4I), but it should be noted
that the cell sampling time in this protocol is not optimal for neutrophils whose airway infiltration
and its resolution is more rapid than that of eosinophils. The number of macrophage/monocytes was
similar regardless of the treatment group assigned. Figure 4J confirms that the recoveries of BAL fluid
were comparable in the study groups.
2.6. Cell Recruitment Studies in Mice
In the first of these we investigated the effect of ADZ 50,000 on the development of allergic
sensitisation to Der p 1. As shown in Figure 5A, post-study levels of total serum IgE were elevated
compared to the vehicle-treated mice. In contrast, animals receiving Der p 1 treated with ADZ 50,000
had serum IgE levels like the control group. A similar pattern was seen when levels of Der p 1-specific
IgE were measured (Figure 5B). However, the Der p 1-dependent increase in allergen-specific IgG1
was not affected by pre-treatment of Der p 1 with ADZ 50,000 (Figure 5C). Unlike Der p 1, Der p 2
administered alone failed to produce an elevation in total serum IgE (Figure 5A). A further aspect of
this study was to test the prophylactic effect of ADZ 50,000 on mice being sensitised to the full extract
of HDM allergens. As shown in Figure 5D, the presence of ADZ 50,000 during sensitisation prevented
elevation of total serum IgE and the development of allergen-specific IgE to any HDM allergen
(Figure 5E). The additional presence of the serine peptidase inhibitor produced no effect beyond that
of ADZ 50,000 alone (Figure 5D,E). Like the study in brown Norway rats (Figure 4), we found that the
assay for allergen-specific IgE and IgG1 (or IgG2a in the case of rats) detected a variable background
in vehicle-treated animals, but in spite of this it was possible to distinguish the effect of sensitisation.
We do not believe the background immunoreactivity represents prior sensitisation because the mice
used in all these studies were all fully isolator-maintained and, moreover, allergen challenge did not
evoke obvious allergic responses in these control animals.
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In the next study, we evaluated the effect of another ADI, Compound 4, on the development of
allergic sensitisation by comparing pre-immune and post-sensitisation IgE levels in individual animals.
Figure 6A,B shows that intratracheal aerosol delivery of mixed HDM allergens in the absence of any
added adjuvant increased total serum IgE and resulted in the development of allergen-specific IgE.
However, inclusion of the ADI compound in the immunisation mixture prevented both responses,
whereas the development of allergen-specific IgG1 was unaffected by ADI treatment (Figure 6C).
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Figure 6. Prophylactic action of Compound 4 against i.t. aerosol sensitisation to an extract of
mixed HDM allergens and its inhibition of acute allergic and innate cell recruitment in C57BL/6
mice challenged with mixed HDM allergens (25 µL, i.t., 10 µg equivalent Der p 1). (A–C) Pre- and
post-immune serum c ncentrations of IgE, HDM allergen-specific IgE and allergen-specific IgG1 in
mice with and without ADI treatment (Compound 4, 10:1 molar ratio to Der p 1) during the intranasal
sensitisation protocol. Responses for individual animals are shown. (D–F) BAL cell profiles in C57BL/6
mice sensitised to mixed HDM allergens following challenge with vehicle or mixed HDM allergens
and the modulating effect of Compound 4. The ADI was administered (25 µL at 40 µM, i.t.) 120 min
prior to i.t. allergen provocation (25 µL, i.t.). Test compound was dosed at a 10:1 molar ratio with
respect to Der p 1. The mixed HDM preparation contained a dose of 10 µg Der p 1. * p < 0.001–0.01
vs. vehicle challenge; † p < 0.01 vs. HDM challenge. (G–I) BAL leukocyte profiles in unsensitised
C57BL/6 mice following i.t. challenge with vehicle or mixed HDM allergens and the modulating
effect of ADI Compound 4 on the innate recruitment of leukocytes. The ADI was administered (25 µL
at 40 µM, i.t.) 15 min prior to i.t. allergen provocation. * p < 0.001, ‡ p < 0.05 vs. vehicle challenge;
† p < 0.001–0.05 vs. HDM challenge. (J) BAL fluid returns in the study groups. * p < 0.01–0.05 vs. other
treatments. Data for individual animals are shown in (D–J). Cross-hairs and whiskers denote mean ±
s.e. mean, respectively.
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We then investigated the recruitment of inflammatory cells to the airways in mice sensitised to
mixed HDM allergens following challenge with the same allergens. The primary purpose was to
discover how these responses were affected by treatment with Compound 4 given 2 h before HDM
allergen provocation. In mice challenged with HDM allergens administered by i.t. aerosol there
was a significant increase in the numbers of nucleated cells recovered by BAL compared to animals
which had been sham-treated with vehicle alone. This was most marked in mice actively sensitised to
HDM allergens. Pre-treatment with Compound 4 prior to challenge attenuated the cell recruitment
(Figure 6D). These overall effects were reflected when specific effects on eosinophils and neutrophils
were considered, with the allergen-dependent recruitment of both being significantly inhibited by the
single dose of Compound 4 (Figure 6E,F).
An interesting feature evident in Figure 6D–F was the ability of the mixed HDM allergens to
evoke cellular responses in sham-sensitised animals that were not evident in mice challenged with
the vehicle. We therefore investigated whether pre-treatment with Compound 4 influenced these
innate responses also. As depicted in Figure 6G–I there were significant reductions in the overall
recruitment of cells, and specifically eosinophils and neutrophils. The ADI compound itself had no
effect on baseline cell numbers in BAL fluid in unchallenged animals (Figure 6G–I). Recovery of BAL
fluid in the treatment groups comprising the studies depicted in Figure 6 were generally consistent
except in the case of sensitised animals that were HDM challenged in whom fluid return was reduced
(Figure 6J).
To explore whether the inhibitory effects of ADI compounds on cell recruitment were due to a
direct effect on Der p 1, as intended by the drug design campaign, we conducted a further study in
mice sensitised to and challenged with OVA. As shown in Figure 7A,B, Compound 5 failed to attenuate
the cell recruitment response following acute challenge with OVA in monosensitised mice, consistent
with exemplar ADI compounds exerting their beneficial effects in HDM challenge by selective action
on Der p 1.
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3. Discussion
This paper presents novel insights into the pharmacology of protease inhibitors designed to target
Group 1 allergens of HDM. We refer to this diverse class of compounds as allergen delivery inhibitors,
although it will be clear from the findings presented herein that the scope of their pharmacological
profile is significantly broader than implied by that name. Using exemplar ADIs from four distinct
chemotypes and with differing mechanisms of inhibitory action, our studies reveal significant
modulation of events ranging from innate immune responses to the recruitment of inflammatory
cells to the airways following acute challenge with a mixture of HDM allergens. Unexpectedly,
one feature of acute treatment with chemically diverse ADI compounds was the inhibition of acute
allergic bronchoconstriction. These actions arise from a designed interaction with the Group 1 HDM
allergen target and not through specific immunosuppression or bronchodilatation.
The importance of protease activity to allergenicity and the progression of allergic disease is
supported by a growing range of evidence which may be briefly summarised thus: (i) facilitation of
inhalant allergen detection by antigen presenting cells; (ii) activation of signal transduction mechanisms
which drive innate immune responses to break tolerance and promote the acquisition of allergic
sensitisation; and (iii) more chronically, activation of IgE-independent mechanisms which result in
cellular transitions and airways pathophysiology of variable reversibility. In the case of (i) and (ii),
it would be appropriate to consider these actions as being forms of adjuvant behaviour. These topics,
specifically the target validation case for Group 1 HDM allergens, have been the subject of recent
review [2,11,12].
The compounds used in these experiments are directed against Group 1 HDM allergens. As these
are inhalant allergens which evoke respiratory symptoms it is therefore appropriate to consider
inhalation of inhibitor drugs as a preferred route of delivery for asthma therapy. Accordingly,
compounds produced in this discovery campaign were required to comply with ‘inhalation by design’
criteria during lead optimisation [2,22]. However, this is not to ignore non-respiratory effects of
these allergens and compounds have been identified which may be developable for systemic use and
therapeutic indications beyond asthma [22]. For asthma, because the inhibitory engagement between
drug and the allergen target occurs at the luminal face of the airway epithelium, one of several factors
relevant to this interaction is the composition of airway surface liquid. Airway surface liquid is rich in
reducing agents, principally glutathione, which provides a means to maximise the proteolytic activity
of the allergen. The pH of airway surface liquid is estimated to be in the range 6.8–7.6 [27–29] which
is optimal for Der p 1 [30]. In severe asthma, exhaled breath condensate measurements suggest that
pH may be reduced [31], but not below levels likely to materially impair enzymatic activity of Der p 1
based on assessment of its pH optimum. In fact, any such acidification would be expected to augment
the protease-dependent effects of Der p 1 mediated through the generation of reactive oxygen and
nitrogen species [2,32].
Using two chemically and mechanistically distinct ADIs, we showed that inhibition of Der p 1
protease activity attenuated the development of allergic sensitisation. The significance of adjuvancy
provided by the protease activity of the allergen was underscored in the study using Compound 4
where mice were sensitised and challenged with the full spectrum of HDM allergens. These data clearly
demonstrate that Der p 1 is an enabler/initiator of allergy to proteins of diverse structure-function.
Previous studies have shown that Der p 1 facilitates sensitisation to ovalbumin and that the potentiation
of allergenicity is dependent on the protease activity of Der p 1 [4,5,33]. Although capable of initiating
IgE synthesis, ovalbumin differs markedly from Der p 1: The former is a comparatively effete allergen
which requires an adjuvant to overcome tolerance and provide a means to cross epithelial barriers
when delivered to the airways. The clear implication of our data is that protease activity of Group 1
HDM must act similarly for unrelated allergens of mite origin. Analogous findings have been made
in fungi with Aspergillus species where protease-containing extracts of A. fumigatus or A. oryzae
convert tolerogenic reactions to ovalbumin into allergic responses and, more specifically where the
serine protease allergen Asp f 13 facilitates the development of allergy to the non-protease allergen
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Asp f 2 [3,34,35]. Given the extent and diversity of the HDM allergen repertoire, and considering that
all allergens generally fall within <2% of protein families [1], it can be inferred that the adjuvant effect
of Group 1 HDM allergens on the overall sensitisation to HDM allergens is a microcosm of their ability
to promote allergic responses to allergens of non-HDM origin. Moreover, the significance of HDM
as allergenic sources indicates that HDM protease allergens are well justified as exemplars of those
allergens which enjoy exclusivity as initiators [8,10].
Whereas inhibition of the protease activity of Der p 1 attenuated the development of
allergen-specific IgE and the recruitment of eosinophils following allergen challenge, it was notable
that in mice neither ADZ 50,000 nor Compound 4 prevented the development of allergen-specific IgG1.
While this may initially seem counter to the concept that Der p 1 cleaves interepithelial junctions to
increase the probability of allergen detection by DCs, there are two important considerations which
have a bearing on these studies. Firstly, to minimise off-target effects of non-optimised test compounds,
animals were electively treated with doses incapable of completely inhibiting the amount of Der p 1
target delivered to the airways and so some immunological response could be anticipated. Secondly,
the serine peptidase allergen components of the HDM allergen repertoire were not targeted and these
are known to contribute to allergen delivery through an ability to cleave TJ adhesion proteins [25].
An inference from these studies is that the cysteine peptidase activity of Der p 1 is central to
the initiation of allergy because its bioactivity drives both allergen delivery and the polarisation
of immune responses towards IgE production. The unrestrained contribution from HDM serine
peptidase allergens is, however, insufficient to drive these responses when Der p 1 is inhibited,
because endogenous serine peptidase inhibitors which are known to be vulnerable to degradation
by Der p 1 [36,37] provide protection against them when the activity of Der p 1 is inhibited.
Other than providing a biosignature of allergen exposure, understanding the functional consequence
of elevated allergen-specific IgG1 is complex because mouse IgG1 signals through both CD16 (FcγRIII),
a stimulatory molecular recognition system, and CD32B (FcγRIIB), which is inhibitory, and both are
widely expressed on murine haematopoietic cells [38,39]. Nevertheless, and regardless of the nuanced
effects of IgG1, our data demonstrate that inhibition of Der p 1 evidently associates with a prophylactic
reduction in the development of IgE on allergen exposure and usefully attenuates hallmark allergic
effector responses when allergic sensitisation has already been established.
Aerosol exposure of rats or mice to allergen challenge elicited an inflammatory cell response
which was observed by sampling of BAL fluid. Pre-treatment with ADZ 50,000 or Compounds 3 or 4
attenuated the response to Der p 1 or mixed allergens, confirming their efficacy against the purified
target and the more realistic, tougher, test posed by the allergen mixture. These experiments were
undertaken with a sampling time which was optimised for the study of eosinophil recruitment, but it
was pleasing to see that neutrophil recruitment was also inhibited.
The mechanism(s) by which ADIs inhibit the acute bronchoconstriction resulting from challenge
with mixed HDM allergens is presently unclear. Of potential relevance is that Der p 1 degranulates
human mast cells in a protease-dependent, IgE-independent manner [40]. The basis of this effect
remains unknown but, interestingly, mast cells express the orphan receptor MRGPRX1 of the
mas-related G-protein coupled receptor family and in airway epithelial cells this receptor has recently
been suggested as a potential target of Der p 1 [41]. By analogy, the effects of the cysteine protease
mucunain (the active pain-producing substance from cowhage (Mucuna pruriens)), is known to be a highly
mast cell dependent, pseudo-allergic response [12,42]. These lines of evidence suggest that one or more
mas-related G-protein coupled receptors may be the target(s) of these proteases in mast cells [12].
The prophylactic effect of protease inhibitors such as Compounds 3 and 4 in preventing
sensitisation to HDM allergens raises questions about the underlying mechanism. We have
previously presented evidence that small quantities of Der p 1 increase epithelial permeability to
well-characterised marker solutes, suggesting that this would increase the probability of allergen
detection by DCs [14,25,43,44] and showed that this effect was due, in part, to proteolysis of the
extracellular domain of the TJ adhesion protein, occludin [14]. Using recombinant CLD1.1 as a model
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we now demonstrate that claudin family adhesion proteins possess cleavage sites for Der p 1 with
similarities to principal sites identified in the MARVEL family member, occludin [14]. The choice of
claudin 1 for exemplification is justified because it is present in all airway epithelial cells and archetypal
of claudin family proteins which have a ‘sealing function’. Its first extracellular domain demonstrates
good (40–70%) identity with the corresponding domains from most other family members (Table 4),
including claudin-18, a non-classical claudin with a lung-restricted expression [15,45,46]. It shares
less identity with those classical claudins (e.g., claudin 10b, claudin 15) which may be categorised as
forming cation-selective components of TJs [12]. Accordingly, the Leu-Leu cleavage site for Der p 1,
which is common to claudin 1 and occludin, is well represented by identity or similarity in the majority
of other claudins; indeed the dyad is well conserved in the claudin repertoire (claudins 1, 3, 4, 5, 7, and
18) (Figure 7) of human bronchial and bronchiolar epithelial cells [47]. However, the cleavage sites
are absent in the other TJ adhesion proteins tricellulin and MARVELD3 which are thought to have
different functions from occludin and claudins (Figure 8).
Consistent with the ability of Der p 1 to attack TJ adhesion proteins we demonstrated that
Der p 1 reduced TER and that this was inhibited by ADZ 50,000. This is anticipated from the
prediction that claudins are cleavage targets for Der p 1 because claudins have a controlling influence
on electrical resistance, whereas occludin regulates epithelial permeability to non-ionic solutes [48–50].
The transepithelial flux of Der p 1 was inhibited by ADZ 50,000 and this was accompanied by a
reduction in the transepithelial flux of Der p 2, implying that the Group 2 allergen depended on the
activity of Der p 1 to augment its transepithelial passage. In support of this, we noted that Der p 2 had
no effect on TER in calu-3 cells.
A further feature arising from this programme is the characterisation of useful tool compounds
for the investigation of HDM protease allergens. This is important because much previous work has
relied on reagents which lack potency, selectivity, and stability. Compound ADZ 50,059 has been
identified as a useful substrate for Group 1 HDM allergens offering high sensitivity and good selectivity.
Illustratively, its measured KM of 15.4 µM contrasts with 250–280 µM for Boc-Gln-Ala-Arg-AMC,
a substrate previously used to study Der p 1 [30,36]. Compound ADZ 50,000 is a potent irreversible
inhibitor of Group I HDM allergens which other investigations performed by us show to be a useful
active site titrant for the quantification of functional active site concentration. To date, E-64 has been
the principal inhibitor used to investigate the protease activity of Der p 1, but as shown here its broad
spectrum of actions against other enzymes, including some serine peptidases, and only moderate
reactivity with Der p 1 limit its utility. The novel reagents used by this study in tandem with a
range of other inhibitors provides an emphatic functional rebuttal to the suggestion that Der p 1 is a
multifunctional protease with both cysteine and serine peptidase activity [36,51]. A consequence of this
claim has been confusion in the literature and consequent uncertainty about the meaning of data in an
unknown number of studies beyond those reporting enzyme multifunctionality [36,51]. This rebuttal is
the first involving direct functional data with a selective active site titrant and supports key inferences
drawn when the crystal structure of Der p 1 was solved [52,53]. It seems likely that the reports of
multifunctionality were consequences of using an inadequately purified protein. The easy potential
for impurities in allergen preparations to lead to erroneous conclusions was highlighted in the present
study where contamination of Der p 2 by proteases was shown to affect its transepithelial disposition
and is reminiscent of other work in which a particularly intransigent serine protease contaminant was
found associated with the major cat allergen, Fel d 1 [54].
In summary, the exemplar ADI compounds described in this study produce effects which suggest
that an allergen-directed, inhalable small-molecule can achieve a broad range of benefits. The essential
key to achieving this spectrum of desirable effects is the identification of a therapeutic target which
belongs to an exclusive cadre of initiator allergens. The combination of a non-human target and an
inhalable inhibitor with root cause intervention potential offers a future line of attack on the Th2 high
asthma phenotype and related allergic diseases using a strategy which has a conceptually simple basis
and an attractive safety profile.
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Table 4. Similarity matrix for first extracellular domains of human claudin (CL) family adhesion proteins created using Clustal Omega. Grey shading indicates
claudins expressed in human bronchi and bronchioles. Note that: (i) some evidence indicates that claudin-7 may be an anion channel-forming rather than a sealing
type claudin; (ii) the similarity data for claudin 10 are based on the canonical claudin 10b sequence; (iii) the data for claudin 18 are based on the canonical sequence of
the A1 isoform (UniProt: P56856).
CL 1 2 3 4 5 6 7 8 9 10 11 12 14 15 16 17 18 19 20 21 22 23 25
1 100 43 61 62 57 60 70 51 60 37 29 24 49 38 26 42 44 64 38 34 34 25 30
2 43 100 45 45 42 49 47 40 49 35 29 22 58 30 26 36 42 55 40 24 24 19 26
3 61 45 100 94 67 80 59 71 80 44 32 25 61 42 31 63 42 57 45 40 40 24 31
4 62 45 94 100 74 85 55 68 83 42 35 28 62 40 34 58 46 53 43 38 38 25 34
5 57 42 67 74 100 72 60 57 70 40 37 24 53 36 34 43 40 49 45 36 36 25 30
6 60 49 80 85 72 100 53 66 98 40 35 26 59 32 32 53 42 57 43 40 40 23 34
7 70 47 59 55 60 53 100 49 53 42 33 26 49 38 32 43 42 60 45 36 36 25 28
8 51 40 71 68 57 66 49 100 66 33 31 28 49 32 34 70 37 45 32 40 40 25 32
9 60 49 80 83 70 98 53 66 100 40 35 26 58 32 32 53 40 57 43 40 40 23 34
10 37 35 44 42 40 40 42 33 40 100 35 18 37 64 30 31 29 42 37 30 29 13 28
11 29 29 32 35 37 35 33 31 35 35 100 17 37 24 27 27 33 32 38 27 26 19 27
12 24 22 25 28 24 26 26 28 26 18 17 100 22 23 27 20 27 24 22 21 21 24 19
14 49 58 61 62 53 59 49 49 58 37 37 22 100 34 34 45 38 47 47 32 32 23 30
15 38 30 42 40 36 32 38 32 32 64 24 23 34 100 27 34 28 38 32 22 22 16 20
16 26 26 31 34 34 32 32 34 32 30 27 27 34 27 100 30 25 28 26 32 31 19 26
17 42 36 63 58 43 53 43 70 53 31 27 20 45 34 30 100 31 47 36 36 36 25 32
18 44 42 42 46 40 42 42 37 40 29 33 27 38 28 25 31 100 38 35 28 27 29 28
19 64 55 57 53 49 57 60 45 57 42 32 24 47 38 28 47 38 100 43 32 32 27 28
20 38 40 45 43 45 43 45 32 43 37 38 22 47 32 26 36 35 43 100 24 24 21 28
21 34 24 40 38 36 40 36 40 40 30 27 21 32 22 32 36 28 32 24 100 100 24 62
22 34 24 40 38 36 40 36 40 40 29 26 21 32 22 31 36 27 32 24 100 100 25 62
23 25 19 24 25 25 23 25 25 23 13 19 24 23 16 19 25 29 27 21 24 25 100 18
25 30 26 31 34 30 34 28 32 34 28 27 19 30 20 26 32 28 28 28 62 62 18 100
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Clustal Omega and Jalview. Colour shading denotes residues scored for conservation and quality. 
Arrows denote cleavage sites for Der p 1 identified in this study. (B) Sequence alignments of TJ-
associated MARVEL domain adhesion proteins (occludin (OCL), tricellulin (TRI), MARVELD3 
(MALD3)). Two isoforms of MARVELD3 are shown. Arrows indicate occludin residues cleaved by 
Der p 1 based on partial scanning of the first extracellular domain [14]. In both panels, the numbers 
appended after the protein identifier indicate the number of residues in each domain. Dyads bounded 
by red boxes denote putative cleavage hot spots for Der p 1 and other Group 1 HDM allergens based 
on the present study and previous work [14]. 
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Dorset, UK), LGC (Teddington, Middlesex, UK), and GE Healthcare, Little Chalfont, 
Figure 8. (A) Multiple sequence alignments of the first extracellular domain of claudins (CLD)
expressed in human lung (claudins 1, 3, 4, 5, 7, and 18) and their consensus sequence created
using Clustal Omega and Jalview. Colour shading denotes residues scored for conservation and
quality. Arrows denote cleavage sites for Der p 1 identified in this study. (B) Sequence alignments
of TJ-associated MARVEL domain adhesion proteins (occludin (OCL), tricellulin (TRI), MARVELD3
(MALD3)). Two isoforms of MARVELD3 are shown. Arrows indicate occludin residues cleaved by
Der p 1 based on partial scanning of the first extracellular domain [14]. In both panels, the numbers
appended after the protein identifier indicate the number of residues in each domain. Dyads bounded
by red boxes denote putative cleavage hot spots for Der p 1 and other Group 1 HDM allergens based
on the present study and previous work [14].
4. Methods and Materials
.1. Materials
Cell culture media and reagents were obtained from Life Technologies, Sigma-Aldrich (Poole,
Dorset, UK), LGC (Teddington, Middlesex, UK), and GE Healthcare, Little Chalfont, Buckinghamshire,
UK. All other materials were sourced as indicated below. Unless otherwise stated, reagents and
solvents for chemical synthesis were readily available from commercial suppliers.
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Analytical LC-MS was performed using a Waters ZQ instrument and purity assessed using a
diode array detector. Chromatography was performed using a Phenomenex Gemini 5.0 × 3.0 mm,
5 µm, C18 column with a flow rate 1 mL/min using solvents A and solvent B according to the following
gradient: Solvents: A: 0.1% v/v formic acid/water; B: 0.1% v/v form ic acid/MeCN; % B: ramping from
5% B to 95% B between 0 min and 3.5 min and then continuing at 95% B for 3.5–5 min.
Compounds were typically purified by standard flash column chromatography using BDH silica
gel, purchased from VWR, or using a Flash Master Personal with Isolute SPE cartridges, purchased
from Biotage. Where necessary, reversed phase preparative LC-MS was performed using the Waters
ZQ instrument. The structures and purities of compounds were assigned using analytical LC-MS and
1H NMR. 1H NMR spectra were run on a Bruker 400 MHz instrument and spectra were analysed using
MestReC. Chemical shifts are given in ppm and coupling constants (J) are quoted in Hz.
4.2. Synthesis of Der p 1 Substrate and Specific Inhibitors
(3S,6S,9S,12S,15S,18S)-1-(2-aminophenyl)-9-butyl-18-carbamoyl-15-(4-hydroxy-3-nitrobenzyl)-
12-(hydroxymethyl)-3-isopropyl-6-methyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazaicosan-20-oic
acid (ADZ 50,059) was identified by high throughput screening (HTS) of a positional scanning library
and prepared by solid-phase synthesis using conventional chemistry [55].
The following tripeptides were synthesized on Wang resin using FMoc protected amino acids
and standard amide coupling procedures [55]. They were subsequently used for the synthesis of ADZ
50,000, and Compounds 1 and 2.
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ADZ 50,000, Compounds 1 and 2 required the synthesis of the corresponding bromomethyl 
ketones as described below (Scheme 1):  
i t s t i f t c rres i r
i l ( ):
To a solution of the corresponding peptide (1 equivalent) in dry tetrahydrofuran (THF)
(2 mL/50 mg of peptide) and dry dimethylformamide (0.2–0.4 mL/50 mg peptide depending upon
amount required to dissolve the peptide) at −20 ◦C (MeOH/ice) was added isobutylchloroformate
(3 equivalents) and N-methylmorpholine (3 equivalents) and the reaction mixture stirred at
−20 ◦C for 30 min. A solution of diazomethane in diethylether (approx. 6 equivalents; 0.15 M
synthesised from Diazogen, made in accordance with Aldrich Technical Bulletin AL-180 https://www.
sigmaaldrich.com/content/dam/sigma-aldrich/docs/Aldrich/Bulletin/al_techbull_al180.pdf) was
added. The reaction mixture was stirred at <0 ◦C for 1 h then allowed to warm to room temperature
and stirred for a further 1 h. A 1:1 mixture of 50% v/v HBr (aqueous) and acetic acid (9 equivalents,
based on amount of HBr added) was then added and the reaction mixture stirred at room temperature
for 30 min. Note that nitrogen is evolved, and the yellow colour disappears. The reaction mixture was
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subsequently diluted with ethyl acetate and washed with an equal volume of water and a saturated
aqueous solution of NaHCO3. The organic layer was dried over MgSO4 and evaporated to give the
desired compound as a white solid. This was used without further purification to generate ADZ 50,000,
Compound 1 and Compound 2.Int. J. M l. Sci. 2018, 19, x 22 of 36 
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Compound 1, an amino ketone, (N-((2R)-1-(((2S)-1-((1-(dimethylamino)-2-oxoheptan-3-
yl)amino)-1-oxopropan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide) was prepared via 
Scheme 2 as described as follows: 
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Compounds 1 and 2 were synthesised from the corresponding bromomethyl ketone by stirring
with the requisite amine according to Scheme 2.
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under nitrogen, was added a solution of dimethylamine (3.8 mL, 2M in THF) and the reaction stirred
at room temperature for 6 h prior to evaporation. The crude residue was purified by reversed phased
preparative LC-MS to give the title compound as a 1:1 mixture of diastereomers at the centre adjacent
to the ketone, as its formate salt (269 mg, 36% over two steps); 1H NMR (400 MHz; d6-DMSO) δ 8.72
(1H, d, J = 7.3), 8.68 (1H, d, J = 7.6), 8.43 (1H, d, J = 7.3), 8.41 (1H, d, J = 7.3), 8.18 (2H, s), 8.02 (1H, d,
J = 7.6), 7.99 (1H, d, J = 7.8), 7.84–7.78 (4H, m), 7.55–7.49 (2H, m), 7.48–7.41 (4H, m), 7.38–7.33 (4H, m),
7.30–7.24 (4H, m), 7.21–7.15 (2H, m), 4.69–4.60 (2H, m), 4.36–4.20 (4H, m), 3.45 (1H, d, J = 17.7), 3.30
(1H, d, J = 17.7), 3.22 (1H, d, J = 17.7), 3.15 (1H, d, J = 17.7), 3.09–3.01 (4H, m), 2.15 (6H, s), 2.07 (6H, s),
1.76–1.64 (2H, m), 1.64–1.41 (2H, m), 1.34–1.10 (14H, m), 0.86–0.81 (3H, m), 0.79–0.74 (3H, m); LC-MS
Rt 1.81 min; purity 97.6%; MS m/z 495 (MH)+.
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Compound 2, also an amino ketone, (N-((2S)-1-oxo-1-(((2S)-1-oxo-1-((2-oxo-1-(pyrrolidin-1-yl)
heptan-3-yl)amino)propan-2-yl)amino)-3-phenylpropan-2-yl)benzamide) was prepared via Scheme 2
as follows:
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c e e 3. Sche atic illustration.
To a solution of potassium fluoride (14 mg, 0.2 mmol, thre equivalents) and 2,6 bis-
(trifluoromethyl)benzoic acid (42 mg, 0.16 mmol, two equivalents) in dry DMF (1 mL) over 4Å
molecular sieve was added a solution of the bromomethyl ketone (40 mg, 0.08 mmol, one equivalent)
in dry DMF (1 mL) and the reaction mixture stirred at room temperature for 3 h. The reaction mixture
was then filtered through a plug of silica, washed with 10% v/v methanol/DCM and then evaporated
to dryness. The crude residue was purified by reversed phase preparative HPLC to give ADZ 50,000
(8 mg, 15%); MS m/z 660 (MH)+.
Compound 3 was synthesised according to the following route (Scheme 4) from Bz-Phe-AlaOH
which had been prepared using standard Fmoc solid phase peptide synthesis.
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o pound 3, ( -((S)-1-oxo-1-(((S)-1-oxo-1-(((S)-1-oxohexan-2-yl)a ino)propan-2-yl)a ino)-3-
phenylpropan-2-yl)benza ide) as prepared as described belo : 
To a solution of Bz-Phe-AlaOH (374 mg, 1.1 mmol) in dry THF (12 mL) and dry DMF (0.5 mL)
at −20 ◦C was add d N-methylmorpholine (375 µL, 3.4 mmol) and isobutylchloroformate (157 µL,
1.2 mmol). The mixture was stirred at this temperat r for 1 h then S-(+)-2-amino-1-hexano (142 mg,
1.2 mmol) in dry DMF (0.5 L) was adde . The mixture was sti red at −20 ◦C for 2 h then allowed
to gra ually warm to room temp rature and sti red for 18 h. The reaction mixture was subsequently
diluted with et yl acetate, washed with a saturat d aqu ous solution of NaHCO3, brine and d ied over
MgSO4. The filtrate was evaporated and the crude resid e purified by flash chromatography on silica
eluting with ethyl acetate to give the title compound as a white solid (360 mg, 82%); 1H NMR (400 MHz;
d6-DMSO) δ 8.59 (1H, J = 8.4), 8.24 (1H, J = 7.3), 7.79–7.75 (2H, m), 7.54– .48 (2H, m), 7.47–7. 1 (2H, m),
7 39–7 5 (2H, m), 7.29–7.23 (2H, m), 7.19–7.1 (1H, m), 4.74–4.60 (1H, m), 4.64 (1H, t, J = 5.6), 4.32–4.24
(1H m), 3.70–3.61 (1H, m), 3.36–3.29 (1H, m), 3.29–3.20 (1H, m), 3.11 (1H, dd, J = 13.6, 3.8), 2.98 (1H,
dd, J = 13.6, 11.1), 1.60–1.58 (1H, m), 1.32–1.14 (8H, m), 0.86–0.79 (3H, m); LC-MS: Rt 2.96 min; purity >
95%; MS m/z 440(MH)+.
Compound 3, (N-((S)-1-oxo-1-(((S)-1-oxo-1-(((S)-1-oxoh xan-2-yl)amino)propan-2-yl)amino)-3-
phenylpropan-2-yl)benzamide) was prepared as described below:
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acetate. The extract was washed sequentially with sodium bicarbonate, deionised water, and brine 
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8.75−8.72 (2H, m, ArH), 8.57 (1H, d, J = 8.3 Hz, NH), 8.38 (1H, d, J = 9.4 Hz, NH), 8.24 (1H, d, J = 7.1 
Hz), 8.02 (1H, d, J = 7.8 Hz, NH), 7.81−7.78 (2H, m, ArH), 5.04 (1H, dd, J = 7.8 and 5.3 Hz, CHCO), 4.52 
(1H, d, J = 9.4 Hz, CHCO), 4.47−4.40 (1H, m, CHCO), 3.60−3.45 (1H, m, NHCH(cyclohexyl), 2.22−2.12 
(1H, m, CHMe2), 1.72−1.64 (4H, m), 1.61−1.54 (1H, m), 1.34−1.17 (7H, m), 1.12−1.04 (1H, m), 1.00 (9H, 
s,t-Bu), 0.89 (3H, d, J = 6.8 Hz, CH3), 0.80 (3H, d, J = 6.8 Hz,CH3). 
N-{(S)-1-[(S)-1-((S)-1-Benzylaminooxalyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-2,2-
dimethyl-propyl}-benzamide (Compound 5) was synthesised as described in our previous work [22]. 
To a solution of N-((S)-1-(((S)-1-(((S)-1-hydroxyhexan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-
oxo-3-phenylpropan-2-yl)benzamide (180 mg, 0.32 mmol) in dry DCM (5 mL) and DMF (0.9 mL) was
added a solution of Dess–Martin periodinane (15% wt solution in DCM, 1.9 mL, 0.65 mmol) dropwise
and the mixture stirred at room temperature for 1 h. The reaction mixture was diluted with ethyl
acetate (20 mL) and a solution of sodium thiosulphate (1 g) in a saturated aqueous solution of NaHCO3
(10 mL) added. The mixture was stirred at room temperature for 15 min, the organic layer separated
and then washed with saturated NaHCO3 (aq.) (2 × 20 mL), brine (2 × 20 mL), dried over MgSO4 and
finally evaporated to dryness. The resulting off-white solid was triturated with ether and dried under
vacuum to give the title compound as a white solid (115 mg, 64%); 1H NMR (400 MHz; d6-DMSO)
δ 9.40 (1H, s), 8.59 (1H, d, J = 8.1), 8.34 (1H, d, J = 7.3), 8.28 (1H, d, J = 7.1), 7.80–7.75 (2H, m), 7.54–7.49
(1H, m), 7.47–7.41 (2H, m), 7.40–7.35 (2H, m), 7.29–7.23 (2H, m), 7.19–7.13 (1H, m), 4.76–4.67 (1H, m),
4.41–4.33 (1H, m), 4.10–4.02 (1H, m), 3.17–3.10 (1H, m), 3.04–2.94 (1H, m), 1.79–1.69 (1H, m), 1.55–1.43
(1H, m), 1.34–1.20 (7H, m), 0.89–0.80 (3H, m); Purity by 1H NMR >95%; MS m/z 538 (MH)+.
N-{(S)-1-[(S)-1-((S)-1-cyclohexylaminooxalyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-2,2-
dimethyl-propyl}-isonicotinamide (Compound 4) was prepared by sequential synthesis involving
an aldehyde intermediate (Scheme 5). To generate this intermediate, a dipeptide acid ((S)-2-{(S)-3,3-
dimethyl-2-[(pyridine-4-carbonyl)-amino]-butyrylamino}-propionic acid), was first prepared
by solution-phase synthesis from an amino acid ester and Boc-(t-Bu)Gly-OH using methods
previously described by us [22]. The dipeptide acid was then coupled with an amino alcohol in
the presence of isobutyl chloroformate/N-methylmorpholine and oxidation with Dess–Martin
periodinane performed to yield an aldehyde product. A modified Passerini reaction was then
employed to produce an α-hydroxyamide from which the desired target compound, N-{(S)-1-[(S)-
1-((S)-1-cyclohexylaminooxalyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-2,2-dimethyl-propyl}-
isonicotinamide, was prepared by Dess-Martin periodinane oxidation at ambient temperature until full
conversion to product had occurred, as judged by LC-MS. The reaction was quenched using saturated
sodium bicarbonate and sodium thiosulphate and stirred before being extracted into ethyl acetate.
The extract was washed sequentially with sodium bicarbonate, deionised water, and brine before being
dried and evaporated prior to purification by reversed-phase preparative HPLC. Desired product
(Compound 4) was characterised as: [M + H]+ 516. 1H NMR ((CD3)2SO, 400 MHz): δ 8.75−8.72 (2H,
m, ArH), 8.57 (1H, d, J = 8.3 Hz, NH), 8.38 (1H, d, J = 9.4 Hz, NH), 8.24 (1H, d, J = 7.1 Hz), 8.02 (1H,
d, J = 7.8 Hz, NH), 7.81−7.78 (2H, m, ArH), 5.04 (1H, dd, J = 7.8 and 5.3 Hz, CHCO), 4.52 (1H, d,
J = 9.4 Hz, CHCO), 4.47−4.40 (1H, m, CHCO), 3.60−3.45 (1H, m, NHCH(cyclohexyl), 2.22−2.12 (1H,
m, CHMe2), 1.72−1.64 (4H, m), 1.61−1.54 (1H, m), 1.34−1.17 (7H, m), 1.12−1.04 (1H, m), 1.00 (9H,
s,t-Bu), 0.89 (3H, d, J = 6.8 Hz, CH3), 0.80 (3H, d, J = 6.8 Hz,CH3).
N-{(S)-1-[(S)-1-((S)-1-Benzylaminooxalyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-2,2-
dimethyl-propyl}-benzamide (Compound 5) was synthesised as described in our previous work [22].
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4.3. Preparation of HDM Allergen and Purification of Der p 1
Continuous solid-phase culture at 25 ◦C and 75% relative humidity in custom-engineered
containment was used to produce populations of Dermatophagoides pteronyssinus. Native HDM
allergen mixtures were prepared from spent culture medium according to our standard operating
procedures [56]. While the conditions under which HDM are grown are known to influence the exact
composition of HDM allergen mixtures, the extract produced by these procedures is designed to
preserve labile bioactivity and is, to the best of our knowledge, representative of the full allergenic
repertoire of HDM. The Der p 1 content of the mixtures was determined by ELISA measurement
(Indoor Biotechnologies, Cardiff, UK) while proteolytic activity was measured using ADZ 50,059
as substrate. Where appropriate, ADZ 50,000 was used as a titrant to measure the concentration of
functional active sites. For most in vivo studies, we used mixed HDM allergens as the reagent for
sensitisation and challenge because this presentation is most representative of the material to which
the airways are subjected in life. HDM mixtures were normalised by reference to Der p 1 content
expressed as µg/mL as previously described [22]. According to this procedure, ‘HDM 1’ means
1 µg/mL Der p 1 and so forth. Batch-wise consistency in the activity of Der p 1 was ensured by the
inclusion of a reducing agent (cysteine or dithiothreitol) in buffers or culture medium. The appropriate
agent was present also in vehicle controls.
The mixed HDM allergens were also used as feedstock for the purification of Der p 1. High-purity
Der p 1 was required for the characterisation of the Der p 1 substrate and for the testing of novel
molecular entities designed as inhibitors of its proteolytic activity. General methods for this purification
have been described in full elsewhere [56]. In brief, 2–3 volumes of Dulbecco’s PBS were added to mixed
HDM allergens with overnight stirring. After centrifugation (30 min, 24,000× g, 4 ◦C), the supernatant
was aspirated, and solid ammonium sulphate added to 50% saturation in the presence of 1 mM
EDTA. After precipitation for >2 h the pellets were collected, and insoluble matter removed from
the reconstituted solution. The soluble fraction then underwent size exclusion chromatography at
pH 7.4 on an ÄktaPurifier system (HiPrep 16/60 Sephacryl S-200 HR, GE Healthcare, UK) with an
elution buffer comprising 0.2 M sodium phosphate containing 0.5 M sodium chloride and 1 mM EDTA.
A fraction containing Der p 1 was collected and then refined using a soybean trypsin inhibitor (SBTI)
column. This cycle of size exclusion and serine peptidase removal was repeated and the final eluate
passed through an Amicon ultrafiltration cell (Millipore, Bedford, MA, USA) with a 10 kDa cut-off
membrane to concentrate and desalt the preparation. After dilution in 20 mM Tris-HCl buffer, pH 8.0,
the sample was then chromatographed on Resource Q (GE Healthcare) using an ÄktaPurifier. Der p 1
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was eluted by gradient chromatography with 0–0.5 M NaCl. Peaks containing Der p 1 were analysed
by SDS-PAGE and MALDI-TOF mass spectrometry (Kratos Axima, Kratos Analytical, UK or Bruker
Flex, Bruker, UK) and combined. Der p 1 was quantified by ultraviolet absorbance spectrometry in a
quartz cuvette at 280 nm using an extinction coefficient of 47,705 M−1 cm−1.
4.4. Der p 1 and Der f 1 Enzyme Activity Assays
These were performed in 96-well plates using a PerkinElmer Multiprobe II Plus HTS EX robot
(PerkinElmer, Seer Green, Buckinghamshire, UK). Reactions consisted of substrate (10 µL at 12.5 µM
final concentration), reaction buffer (70 µL potassium phosphate buffer, pH 8.25 containing 1 mM
EDTA) and dithiothreitol (DTT, 10 µL with a final concentration of 1 mM). Catalysis was initiated
with the addition of 10 µL Der p 1 or Der f 1 dissolved in reaction buffer at 2.5 µg/mL and
the reaction followed at 30 ◦C by measurement of fluorescence (excitation/emission 330/420 nm)
using either a Fusion Alpha-FP or Envision plate reader fitted with a temperature-controlled carrier
(PerkinElmer, UK).
Using a modification of the procedure described above with mixed HDM allergens containing the
equivalent of 40 nM Der p 1, studies were undertaken to compare the effects of ADZ 50,000 with a
range of standard enzyme inhibitors (Sigma-Aldrich).
Enzymatic activity in a commercial Der p 2 preparation (Indoor Biotechnologies, UK) was assayed
at ambient temperature using 200 µM N-Bz-Phe-Val-Arg-p-nitroanilide hydrochloride (Sigma-Aldrich,
UK) and 3 µM Der p 2 in PBS containing 1 mM DTT and in the absence and presence of 100 µM
4-(2-aminoethyl) benzenesulphonyl fluoride hydrochloride (AEBSF, Sigma-Aldrich, UK). A405 nm was
measured 15 min after reaction.
4.5. Assay of Cathepsin B
Assays comprised 10 µL Abz-Gly-Ile-Val-Arg-Ala-Lys-DNP-OH (Merck, Watford, Hertfordshire,
UK, 5.9 µM final concentration), 70 µL of reaction buffer (0.1 M NaAc-HAc, pH 4.5, 0.2 M NaCl),
and 10 µL of DTT (2.5 mM final). Reactions were initiated by adding 10 µL of human liver cathepsin B
dissolved in reaction buffer to give final concentration of 0.5 nM. Reactions were performed at 30 ◦C
and followed kinetically by excitation/emission at 320/420 nm. For inhibitor studies, the reaction
buffer volume was 60 µL and inhibitor added in 10 µL aliquots.
4.6. Assay of Cathepsin H
Assays comprised 10 µL L-Arg-7-AMC (Sigma-Aldrich, 150 µM final concentration), 70 µL of
reaction buffer (37.5 mM KH2PO4, 37.5 mM K2HPO4, 1 mM EDTA, pH 6.8), and 10 µL cysteine (3 mM
final). Reactions were initiated by adding 10 µL of human liver cathepsin H dissolved in reaction buffer
at a final concentration of 0.4 µg mL−1. Reactions were monitored at 30 ◦C with excitation/emission at
360/460 nm. Buffer volume was 60 µL when using an inhibitor (10 µL).
4.7. Assay of Cathepsin K
Assays comprised 10 µL (Z-Leu-Arg)2–Rhodamine 110 (Merck) (1.25 µM final), 70 µL of reaction
buffer (50 mM MES pH 5.5, 2.5 mM EDTA, 10% v/v DMSO), and 10 µL DTT (2.5 mM final). Reactions
were started by adding 10 µL of cathepsin K dissolved in reaction buffer to give a final concentration of
0.075 nM. Reactions were monitored at 30 ◦C with excitation/emission at 485/535 nm. Buffer volume
was 60 µL when using an inhibitor (10 µL).
4.8. Assays for Cathepsin L and Cathepsin S
Assays comprised 10 µL of Z-Phe-Arg-AMC substrate (Sigma-Aldrich, 10 µM final concentration
in the cathepsin L assay, 20 µM in the cathepsin S assay), 70 µL reaction buffer (400 mM sodium
acetate buffer, pH 5.5 containing 4 mM EDTA for cathepsin L and 0.1 M sodium phosphate buffer,
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pH 7.5 containing 2 mM EDTA for cathepsin S), and 10 µL DTT (8 mM and 2 mM final concentrations,
respectively). Reactions were initiated by adding 10 µL of human liver cathepsin L or recombinant
human cathepsin S dissolved in reaction buffer to give final concentrations of 0.29 nM and 2.5 nM,
respectively. Reactions were monitored at 30 ◦C with excitation/emission at 360/460 nm.
4.9. Assay of Thrombin
Assays comprised 10 µL Bz-Phe-Val-Arg-AMC (Merck, 73 µM final concentration), 70 µL of
reaction buffer (10 mM HEPES, pH 8.0, 5 mM CaCl2, 0.02% v/v NaN3) and started by adding 10 µL of
human plasma thrombin dissolved in reaction buffer (1 nM final). Reactions were performed at 30 ◦C
and followed by excitation/emission at 370/450 nm. Inhibitor was added in 10 µL aliquots, as above.
4.10. Assay of Trypsin
This comprised 10 µL N-Bz-Phe-Val-Arg-p-nitroanilide hydrochloride (Sigma-Aldrich, 200 µM
final concentration) and 70 µL of reaction buffer (PBS). Reactions were started at 30 ◦C by adding
10 µL of trypsin (2 nM final) and monitored by A405 nm. Inhibitor was added in 10 µL aliquots.
For comparative studies using trypsin (2 µg/mL) and Der p 1 (20 µg/mL), the above conditions were
modified to permit the inclusion of 10 µL DTT (1 mM final) and in these experiments AEBSF (80 µM)
or ADZ 50,000 (80 µM) were used as inhibitors.
4.11. Assay of Chymotrypsin
Assay mixtures comprised 10 µL N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide (Sigma-Aldrich,
200 µM final), 70 µL of reaction buffer (0.1 M Tris-HCl, 10 mM CaCl2, 250 mM NaCl, pH 8.0).
Reactions were monitored by A405 nm at 30 ◦C after adding 10 µL of chymotrypsin (TLCK-treated,
Sigma-Aldrich) in reaction buffer (2 nM final). Inhibitor was added in 10 µL aliquots, as above.
For comparative studies using chymotrypsin (2 µg/mL) and Der p 1 (20 µg/mL), the above conditions
were modified to permit the inclusion of 10 µL DTT (1 mM final) and in these experiments AEBSF
(400 µM) or ADZ 50,000 (40 µM) were used as inhibitors.
4.12. Analysis of Inhibitor Kinetics
Inhibitor kinetics were analysed by the progress curve method essentially as described [57].
For irreversible inhibitors, data were fitted by computational non-linear regression and the apparent
inactivation rate constant (kobs) was calculated from the Equation (1):
[P]t =
Vz
kobs
(
1− e−kobs ·t
)
(1)
where [P]t is the product concentration at time t.
Vz is the velocity of the uninhibited reaction.
kobs is a pseudo first order rate constant.
For reversible inhibitors, IC50 values were calculated using conventional procedures.
4.13. Expression of Claudin 1.1
RNA was extracted from confluent cultures of Calu-3 cells grown as previously
described [12,21,24,58] and cDNA synthesised according to manufacturer protocol (Qiagen,
Manchester, UK). cDNA corresponding to the first extracellular domain of claudin 1, henceforth
designated CLD1.1, was amplified using 5′-TAC ATA TGC AGT GGA GGA TTT ACT CCT ATG
CCG GCG A-3′ as forward primer and 5′-ACG GAT CCT TAA CGG GTT GCT TGC AAT GTG CTG
CTC AGA-3’ as reverse primer. PCR products were sub-cloned into pET 22b+ and transformed into
E. coli expression strain BL21DE3 plySs. After induction by 1 mM IPTG this yielded a 6 kDa peptide
on SDS-Tricine PAGE consistent with that predicted for CLD1.1 and which was absent in negative
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controls lacking IPTG. The CLD1.1 band was subjected to in-gel digestion by trypsin and the resultant
fragments analysed by MALDI-TOF in positive reflectron mode. The resulting mass spectrum revealed
two major fragments (m/z 620.2 and m/z 1764.6) which correspond to the sequences 1Met-Gln-Trp-Arg4
and 39Val-Phe-Asp-Ser-Leu-Leu-Asn-Leu-Ser-Ser-Thr-Leu-Gln-Ala-Thr-Arg54 confirming identity with
a residue coverage of 37%.
To study its proteolysis by Der p 1, recombinant CLD1.1 was separated by SDS-Tricine PAGE and
the band containing the peptide excised from the gel. The gel slices were successively washed with
10 mM ammonium bicarbonate buffer (pH 8.9), 50% MeCN and 100% MeCN and then freeze-dried.
Reactions were performed by exposing the dried gel slices to Der p 1 in PBS containing 1 mM DTT
and incubating at room temperature. Inhibitor studies were performed by pre-treating Der p 1 (4 µM)
with either ADZ 50,000 (400 µM) or AEBSF (4 mM) for 10 min prior to addition to CLD1.1 with
a 1:10 v/v dilution. Negative controls comprised Der p 1 or CLD1.1 incubated alone in reaction
buffer. After treatment with Der p 1, 10 µL of supernatant from each reaction mixture was analysed
by LC-MS. Capillary liquid chromatography was performed using a 5 µm reversed-phase column
(BioBasic-18, 100 × 0.18 mm; ThermoElectron, Hemel Hempstead, Hertfordshire, UK) at 2 µL/min
using a Surveyor MS pump coupled to the electrospray source of an ion trap mass analyser (LCQ
Deca XP Plus, ThermoElectron, UK). Samples were eluted by gradient chromatography (0.1–30%
B in A over 35 min, 30–50% B in A over 10 min followed by 50–80% B in A over 5 min, where A
was aqueous 0.1% v/v formic acid and B was 0.1% v/v formic acid in MeCN. Mass spectra were
acquired in full scan mode (m/z 300–1800) and the three most abundant ions subjected to MS/MS
analysis in data-dependent acquisition mode with dynamic exclusion. Acquired MS/MS spectral
data were searched against a custom database created for this experiment using BioworksBrowser
and the TurboSEQUEST algorithm. Search parameters were declared as free cysteine and undefined
enzyme. The molecular mass range was set to 600–3500 Da and filters applied as follows (∆cn: ≥0.1;
Xc (± 1, 2, 3) 1.5, 2.0, 2.5; protein probability: ≤1 × 10−3. Fragments were evaluated according to their
scores to verify the characterisation.
4.14. Cell Culture
Calu-3 cells (American Type Culture Collection) were cultured as previously described by us and
is a favoured model system because they are of human origin, retain effective tight junctions (TJs) and
form polarised monolayers which develop substantial transepithelial resistance [24,58]. These cells are
well characterised as responding to HDM allergens through various mechanisms present in primary
cultures of human airway epithelial cells [12,20,21,58].
For experiments involving measurements of permeability and transepithelial electrical resistance
(TER), calu-3 cells were grown to confluence on 6.5 mm diameter, 0.1 µm pore polycarbonate Transwell
filters (Corning® Costar®) as described [14]. Treatments in serum-free minimum essential medium with
Earle’s salts (EMEM) were applied to the apical compartment of each well and the plates incubated
at 37 ◦C in a humidified 5% CO2/air atmosphere. TER was measured using an EVOM epithelial
volt/ohm meter (World Precision Instruments, Sarasota, FL, USA) and medium harvested from both
compartments at the end of the experimental treatment.
A549 cells were cultured in 12-well plates (Corning® Costar®) using methods described
elsewhere [58]. At confluence, cells were washed with serum-free EMEM and experimental treatments
applied for 8 h at 37 ◦C in a final volume of 1 mL. Treatment medium was harvested and replaced by
1 mL serum-free medium and incubation continued for 16 h. The medium was harvested, centrifuged
(10,000× g, 30 s) to sediment non-adherent cells and the supernatants stored at −20 ◦C. Whole cell
protein extracts were prepared by the addition of 1 mL boiling 2% SDS w/v in 312 mM Tris, pH 6.8).
Protein concentration was measured using the Biuret method.
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4.15. Studies Performed In Vivo
These studies were compliant with requirements of the Animals Scientific Procedures Act
(UK) in an AAALAC-accredited facility and were subject to prior ethical review. Acute tolerability
investigations performed with the test substances prior to conduct of these studies did not reveal any
obvious adverse events over a 24 h period following dosing.
4.16. Allergic Responses in Rats
Animals (Brown Norway, 250–350 g, Charles River, Ormiston, UK) were housed under isolation
and randomly assigned to treatment groups. Rats were sensitised to HDM allergen mixture,
with aluminium hydroxide adjuvant, or vehicle on days 0, 7, and 14 by intraperitoneal (i.p.) injection
(0.5 mL). On day 17 the animals were briefly anaesthetised with isoflurane in oxygen and sensitisation
treatments administered as intratracheal aerosols (delivery volume to airways 100 µL) using a
Penn-Century IA-1C/FMJ-250 dosing device.
For measurement of acute allergic bronchoconstriction and airways hyperreactivity, animals were
anaesthetised on day 21 with pentobarbitone (100 mg/kg i.p.) and ventilated via a tracheal cannula
(approximately 7 mL/kg, 1 Hz) with a 50:50 v/v mixture of oxygen in air. The anaesthetised, ventilated
animals were then paralysed with norcuron (4 mg/kg i.m., MSD, Hoddesdon, Hertfordshire, UK).
Ventilation was monitored using a flow transducer (Fleisch, type 0000) in-line with the respiratory
pump. Coincident pressure changes within the thorax were monitored directly using an intrathoracic
cannula, enabling display of the pressure differential between trachea and thorax. Airways resistance
(RL) and dynamic compliance (Cdyn) were calculated for each respiratory cycle on a digital electronic
respiratory analyser (PMS, Mumed Ltd., London, UK). Blood pressure and heart rate were also
routinely recorded. Animals were challenged by vehicle of HDM allergen mixture (with or without
ADI compounds) using a Penn-Century aerosoliser inserted into the trachea. Dose delivery volume to
the airways was 100 µL. Acute bronchoconstrictor responses arising from the challenge were measured
as the change in RL from baseline. One hour after challenge the responses to a dose of acetylcholine
(100 µg/kg, 1 mL/kg) and then to a dose of adenosine (10 mg/kg, 1 mL/kg) were recorded. At the end
of the study, the animals were euthanised by pentobarbitone overdose. As a further control, a group of
sensitised animals was challenged by i.t. aerosol on day 21 and airways hyperreactivity measurements
made 24 h later as described above.
For studies of allergen-induced leukocyte accumulation, animals were briefly anaesthetised
(isoflurane in oxygen) on day 21 after the beginning of the sensitisation procedure and vehicle, HDM
allergen mixture or HDM allergen mixture with ADI compound delivered from a Penn-Century
aerosoliser as previously described. Animals were then allowed to recover from anaesthetic to enable
assessment of cell recruitment to the lungs to be made 48 h after challenge. At this point animals
were killed with pentobarbitone (250 mg/kg i.p.) and the lungs lavaged via a tracheal cannula using
3 × 4 mL aliquots of Hanks’ balanced salt solution (HBSS) containing 10 mM EDTA and 25 mM
HEPES. The recovered cells from each animal were pooled and the total volume recovered adjusted
to 12 mL using HBSS. Total cells were counted (ADVIA®, Bayer Healthcare, Diagnostic Division,
Reading, Berkshire, UK) and smears made by diluting recovered fluid (to approximately 106 cells/mL)
and pipetting an aliquot (100 mL) into a centrifuge (Cytospin, Shandon, UK). Smears were air-dried,
fixed for 10 s using methanol, and stained with buffered eosin (10 s) and methylene blue/Azur
(5 s) (Speedy-Diff, Clin-Tech Ltd., Guildford, Surrey, UK) to differentiate eosinophils, neutrophils,
macrophages/monocytes, and lymphocytes. A total of 500 cells in each sample were counted by light
microscopy at ×1000 using an oil immersion objective.
In both studies, a terminal blood sample was taken from each animal and serum prepared for the
measurement of immunoglobulins.
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4.17. Allergic Sensitization Studies in Mice
Mice (female Balb/c or C57BL/6 depending on study, 20 ± 2 g, Charles River/BioLASCO) were
maintained in an isolator facility using individually ventilated cages (Allentown IVC Racks, 36 Mini
Isolator System, Allentown, NJ, USA) which had been autoclaved before use. The environmental
regime was 22–24 ◦C/60–80% relative humidity on a 12 h light/dark cycle. There was ad libitum access
to reverse osmosis-purified water and food (MF-18 laboratory rodent diet). Where the investigation
required both pre- and post-study serum samples, the pre-study samples were taken from the
retro-orbital sinus on acclimatisation in the isolator. Animals were randomly assigned to groups
and sensitised to a natural mixture of HDM allergens, Der p 1 alone, Der p 2 alone, or treated
with vehicle on day 0, 7, and 14. The route of administration, i.p. or intranasal, was according to
predetermined study protocol. Animals were challenged under anaesthetic cover by i.t. aerosol on
day 21 using a Penn-Century IA-1C/FMJ-250 aerosoliser (20 µL/mouse). On day 22 the animals
were anaesthetised with propofol (AstraZeneca, 10 mg/mL, 50 µL/mouse, i.v.) and terminal blood
samples taken from the retro-orbital sinus. Then BAL was performed using 2 × 0.25 mL or 3 × 0.5 mL
aliquots of PBS according to study design. The returns were combined, fluid volumes measured, and
cells enumerated (Sysmex XT-1800iV, Sysmex, Kobe, Japan). A similar approach was used in studies
involving ovalbumin (OVA) challenge in animals sensitised i.p. to OVA with Al(OH)3 as adjuvant.
4.18. ELISA Measurements
Cytokines were assayed using kits and according to manufacturer protocol (Biosource Europe,
Nivelles, Belgium). Der p 1 and Der p 2 were quantified by ELISA using reagents obtained from Indoor
Biotechnologies, UK.
Total IgE was measured by sandwich ELISA in Corning® Costar® high binding 96-well
microplates. For rat serum, plates were coated overnight with mouse anti-rat IgE (clone B41-1,
BD Biosciences Europe, Wokingham, Berkshire, UK) in carbonate-bicarbonate buffer and blocked
using DPBS with 0.05% v/v Tween® 20 (DPBST) containing 10% v/v foetal bovine serum. Rat serum
samples or IgE standards (BD Biosciences) were diluted in Can Get Signal® Solution 1 (2B Scientific,
Upper Heyford, Oxfordshire, UK) and incubated on the plate for 15 h at 4 ◦C. After washing,
the secondary antibody (biotin-conjugated mouse anti-rat, clone B41-3, BD Biosciences) and
streptavidin-horseradish peroxidase were added in Can Get Signal® Solution 2 and the plate incubated
at room temperature for 3.5 h. After washing, substrate solution (3,3′,5,5′-tetramethylbenzidine
dihydrochloride in phosphate-citrate perborate buffer) was added to each well and the reaction
terminated by addition of 2 M sulphuric acid after incubation in the dark for 5–15 min. Plates were
read at 450 nm using an automated plate analyser and data quantified by interpolation from standard
curves. A similar procedure was used for the measurement of mouse IgE using an OptEIA™ set
(BD Biosciences).
Allergen-specific immunoglobulin assays were performed by indirect ELISA. Plates were coated
overnight at 4 ◦C with Der p 1 or mixed HDM allergens in carbonate-bicarbonate buffer and blocked
according to our standard procedures. Samples of serum were then added and incubated as described
before addition of the appropriate rat (RG7/1.30 or B41-3, BD Biosciences) or mouse (BD OptEIA or
MCA336P, AbD Serotec, Kidlington, UK) secondary antibodies diluted in Can Get Signal® Solution 2.
Assays were developed as described above and data reported as absorbance at 450 nm.
4.19. BAL Analysis by Flow Cytometry
Polychromatic flow cytometry of BAL fluid samples was performed on a BD FACSAria™
instrument (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA) with data acquisition and
analysis performed using FACSDiva™ software. Unless stated otherwise, antibodies for these
studies were obtained from BD Pharmingen and comprised MHC class II-FITC conjugate (antibody
2G9), CD11c-allophycocyanin conjugate (antibody HL-3), CD11c-phycoerythrin/Cy7 conjugate,
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CD3-phycoerythrin/Cy5 conjugate (antibody 145-2C11), B220 (CD45R)-phycoerythrin/Cy5 conjugate
(antibody RA3-6B2), CCR3-phycoerythrin (antibody 83101, R&D Systems, Abingdon, Oxfordshire,
UK). FcγR blocking agent was antibody 2.4G2. Dendritic cells were enumerated as non-autofluorescent
CD3/B220−, MHC II+, CD11c+. Eosinophils were SSChigh, CCR3+, moderate CD11c+, low-absent
MHC II, B220/CD3−.
4.20. Data Presentation and Statistical Analyses
Data are presented as mean values ± s.e. from the indicated number of observations.
Significance was determined using one-way analysis of variance with post hoc testing using the
Student–Newman–Keuls procedure in SigmaPlot vs. 12.0 unless stated otherwise. A probability value
of p < 0.05 was considered statistically significant.
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Abbreviations
Abz aminobenzoyl
ACh acetylcholine
ADI allergen delivery inhibitor
Ado adenosine
ADZ 50,059 (3S,6S,9S,12S,15S,18S)-1-(2-aminophenyl)-9-butyl-18-carbamoyl-15-(4-hydroxy-3-nitrobenzyl)-
12-(hydroxymethyl)-3-isopropyl-6-methyl-1,4,7,10,13,16-hexaoxo-2,5,8,11,14,17-hexaazaicosan-
20-oic acid
AEBSF 4-(2-aminoethyl)benzenesulphonyl fluoride
AMC 7-amino-4-methylcoumarin
BAL bronchoalveolar lavage
Bz benzoyl
CH2Ph benzyl
CLD1.1 extracellular domain 1 of claudin-1
DCM dichloromethane
Der f Dermatophagoides farinae
Der p Dermatophagoides pteronyssinus
DMF dimethylformamide
DMSO dimethyl sulphoxide
DNP 2,4-dinitrophenol
DTT dithiothreitol
E-64 trans-epoxysucciny-L-leucyl-amido (4-guanidino) butane
EDTA ethylenediaminetetraacetic acid
EMEM minimum essential medium with Earle’s salts
GM-CSF granulocyte macrophage-colony stimulating factor
HBSS Hanks’ balanced salt solution
HDM house dust mite
HEPES 4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid
HPLC high performance liquid chromatography
HTS high-throughput screening
i.p. intraperitoneal
iPr isopropyl
IL interleukin
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IPTG isopropyl β-D-1-thiogalactopyranoside
i.t. intratracheal
LC-MS liquid chromatography-mass spectrometry
MALDI-TOF matrix-assisted laser desorption ionisation time-of-flight mass spectrometry
MeCN acetonitrile
MES 2-morpholinoethanesulphonic acid
NaAc-AcH sodium acetate-acetic acid
NMR nuclear magnetic resonance
OVA ovalbumin
PAGE polyacrylamide gel electrophoresis
PAR protease-activated receptor
PBS phosphate-buffered saline
SDS sodium dodecyl sulphate
TER transepithelial electrical resistance
THF tetrahydrofuran
TJ tight junction
TLCK Nα-p-tosyl-L-lysine choromethyl ketone
TPCK N-p-tosyl-L-phenylalanine chloromethyl ketone
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